A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series

  title={A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series},
  author={Run Yu and Nicholas N. Nissen and Andrew E Hendifar and Laura Tang and Yuli Song and Yuan-jia Chen and Xuemo Fan},
Objective The aim of the study was to address the origin and natural history of malignant insulinoma. Methods Retrospective review of medical records of patients diagnosed with insulinoma at Cedars-Sinai Medical Center between 2000 and 2015 was conducted. Hormonal expression in tumor specimens was examined by immunostaining. Results All the 9 patients with malignant insulinoma (35% of 26 patients with insulinoma) already had liver metastasis at hypoglycemia presentation with bulky cumulative… 
Insulinoma: A retrospective study analyzing the differences between benign and malignant tumors.
A Malignant Metastatic Insulinoma as the First Clinical Presentation of Multiple Endocrine Neoplasia Type 1: A Case Report
An uncommon case whose early diagnosis of MEN1 allowed the genetic study, and consequently helped the genetic counseling and early diagnosed of the affected patients.
Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis.
  • H. Gao, Wenquan Wang, Liang Liu
  • Medicine
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • 2019
Malignant Insulinoma Is Largely Derived From Nonfunctioning Pancreatic Neuroendocrine Tumors: A Contemporary View.
  • R. Yu
  • Medicine
  • 2020
It is can now confidently say that malignant insulinoma is largely derived from NF PNET, with rare exceptions.
Malignant Insulinoma with Multiple Liver Metastases and Hypercalcitoninemia in a Patient with Type 2 Diabetes Mellitus Presenting as Recurrent Episodes of Diaphoresis due to Severe Hypoglycemia
A 66-year-old man with long-standing type 2 DM who presented with recurrent episodes of diaphoresis due to severe hypoglycemia despite the withdrawal of insulin therapy, hypercalcitoninemia, and biochemical and radiological findings suggestive of metastatic malignant insulinoma died from acute renal failure.
Metastatic insulinoma presenting 14 years after benign tumour resection: a rare case and management dilemma
A 60-year-old woman who underwent successful surgical resection for a low grade non-functioning pancreatic neuroendocrine tumour (pNET) is presented, with no biochemical or radiological features of recurrence on follow-up visits for 5 years.
Surgical management, pre-operative tumor localization and histopathology of 80 patients operated for insulinoma.
The majority of tumors can be localized by conventional imaging including EUS, and invasive methods may be a useful diagnostic tool in case of non-visible tumors.
Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumors
The concurrent expression of UCH-L1 and α-internexin in pancreatic neuroendocrine tumors was significantly associated with better overall survival and disease-free survival in the combination of both cohorts and the prognostic value of both proteins was validated in patients with stage II and III tumors.
Interpretation of Unexpectedly High Levels of Endocrine Tumor Markers.
  • R. Yu
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2018
UHLETMs provide endocrinologists great opportunities to learn the basic biology and measurement of ETMs and are exciting clinical research opportunities which may lead to discovery of new diseases and new mechanisms of measurement interference.


Giant Insulinoma: A Report of 3 Cases and Review of the Literature
Giant insulinomas are characterized by focal expression of insulin and high rates of liver metastases and long-term follow-up is mandatory in these patients, as recurrence is expected after primary surgery.
Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients.
The short median survival in patients with metastatic disease suggests that the frequent practice of observation in this patient subgroup needs to be reexamined and that continued investigation of regional and systemic therapies with novel agents is warranted.
Malignant Metastatic Insulinoma—Postoperative Treatment and Follow-up
It is concluded that the necessity to treat debiliating and life-threatening hypoglycemia in metastatic malignant insulinoma warrants the option of radical endocrine surgery in combination with extended and repeated postoperative chemoembolization of liver metastases.
Improved Contemporary Surgical Management of Insulinomas: A 25-year Experience at the Massachusetts General Hospital
Pancreatic insulinomas can be readily localized preoperatively with modern imaging to avoid unsuccessful blind pancreatic resection and achieves long-term disease-free survival in the absence of lymphovascular invasion.
Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery.
The personal experience with insulin-secreting carcinoma of the pancreas was reviewed to determine the clinical course and the role of surgery in this disease.
Chromosomal instability predicts metastatic disease in patients with insulinomas.
This study shows that chromosomal instability, as defined by total number of gains and losses > or =8, rather than parameters such as tumor size and proliferation index, is the most powerful indicator for the development of metastatic disease in patients with sporadic insulinoma.
Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia.
Everolimus appears to be a new effective treatment for patients with metastatic insulinoma and refractory hypoglycemia, and Tolerance should be carefully monitored.
Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Conventional contraindications to surgical resection, such as superior mesenteric vein invasion and nodal or distant metastases, should be reconsidered in patients with advanced neuroendocrine tumors.